2014 Fiscal Year Final Research Report
Novel treatment for triple negative breast cancer using Poloxamer
| Project/Area Number |
23591912
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Keywords | 癌ナノテクノロジー / トリプルネガティブ乳癌 / ミセルナノ粒子 |
|---|
| Outline of Final Research Achievements |
Poloxamer was toxic to triple negative human breast cancer cells MDA-MB-231 in culture as evidenced by propidium iodide assays compared with human mammary epithelial (non-cancer) cells MCF12A. Poloxamer had significant cytotoxicity against MDA-MB-231 than MCF12A by the LDH assay. Poloxamer was not associated with cell proliferation in both MDA-MB-231 and MCF12A.
oPloxamer inhibited the growth of breast cancer tumors in intravenous administration. However, Ploxamer did not inhibit the growth of breast cancer tumors in the oral administration.
|
| Free Research Field |
外科腫瘍学
|
